• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA to present at Bio€quity Europe

Niel (Belgium), 14 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that Acting CEO Marc Dechamps will present at Bio€quity Europe, which takes place from 14-16 May in Ghent, Belgium.

The presentation will provide an overview of the Company as well as ongoing and planned clinical trials for the development of its directly injectable formulations of cancer immunotherapies based on its innovative mRNA TriMix platform. Details for the presentation are as follows:

Date: Tuesday 15 May 2018
Time: 16:40-17:00
Location: Level 1+, Priorzaal, Het Pand, Ghent University

Bio€quity Europe is a life science focused investor and partnering event organised by BioCentury, now celebrating its 19th annual meeting. It has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals.


About eTheRNA Immunotherapies

eTheRNA immunotherapies is a clinical-stage company working to deliver innovative cancer immunotherapies from its proprietary mRNA-based TriMix platform. eTheRNA’s goal is to commercialise these immunotherapies to deliver long lasting clinical remission to a broad range of cancer patients.

eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is backed by leading international life sciences investors.

About TriMix

The TriMix platform, on which eTheRNA’s immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work synergistically to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and so mobilize the immune system to attack cancer cells through inducing a T-cell response.

Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clear clinical benefits in advanced melanoma patients.

The Phase 1b study, E011-MEL, recruited its first patient in June 2017 and is assessing two different doses of ECI-006.

Further clinical studies for TriMix immunotherapies are planned to initiate in 2018/19, focused on melanoma and breast cancer indications. These and further studies are designed to determine the optimal route of administration and confirm the potential of TriMix-based treatments as a cornerstone for cancer immunotherapy, both alone and in combination with checkpoint inhibitors.

Further information is available at http://www.etherna.be/.

Contact information

Marc Dechamps
Acting CEO
+32 3 369 17 40

Citigate Dewe Rogerson
Mark Swallow, David Dible, Isabelle Andrews
+44 (0)20 7638 9571